Outcome of the RDAF 2023 General Assembly meeting

29 Mar, 2023

The Rare Disease Action Forum (RDAF) held its annual General Assembly meeting on 28 March 2023.

During the meeting, the RDAF Secretariat presented an overview of the Association’s activities in 2022 and an outlook for 2023. The RDAF President underlined the progress achieved since the creation of the RDAF in 2017 and the role of the RDAF in the Swiss rare disease community. The RDAF will pursue its activities in 2023 to raise awareness and work towards an improved framework for rare diseases in Switzerland.

The General Assembly elected the following candidates for the RDAF Board of Directors: Shayesteh Fürst-Ladani (SFL Pharma), Jasmin Barman-Aksözen (Swiss Society for Porphyria), Rea Lal (Pfizer), Matthias Langenfeld (Takeda), Bettina Nauli (Alexion), Jacqueline de Sá (ProRaris), Alessandro Strebel (Roche) and Raffaella Willmann (FSRMM). Shayesteh Fürst-Ladani was re-elected as RDAF President.

RDAF hosts multi-stakeholder workshop on post-marketing registries

The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...

RDAF Newsletter

We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include: Overview of the latest policy developments relevant for the rare disease field...